|
1) Boku N, Yamamoto S, Shirao K, et al. Randamized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). In: American Society of Clinical Oncology Annual Meeting. 2007
|
|
|
|
|
2) Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008; 9: 215-21
|
|
|
|
|
3) 駒形浩史, 米田修一, 酒井 洋, 他. 肺癌に対するCDDP(≧60mg/m2)併用化学療法の外来実施可能性の検討. In: 第5回臨床腫瘍学会学術集会. 2007
|
|
|
|
|
|
4) Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004; 22: 229-37
|
|
|
|
|
|
5) Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003; 21: 60-5
|
|
|
|
|
|
6) Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335-42
|
|
|
|
|
|
7) Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007; 25: 1539-44
|
|
|
|
|
|
8) Chen HX, Mooney M, Boron M, et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol. 2006; 24: 3354-60
|
|
|
|
|
|
9) Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351: 337-45
|
|
|
|
|
|
10) Weaver A, Young AM, Rowntree J, et al. Application of mobile phone technology for managing chemotherapy-associated side-effects. Ann Oncol. 2007; 18: 1887-92
|
|
|
|
|
|
11) Kelly DF, Faught WJ, Holmes LA. Ovarian cancer treatment: the benefit of patient telephone follow-up post-chemotherapy. Can Oncol Nurs J. 1999; 9: 175-8
|
|
|
|
|
|
12) Majem M, Galan M, Perez FJ, et al. The oncology acute toxicity unit (OATU): an outpatient facility for improving the management of chemotherapy toxicity. Clin Transl Oncol. 2007; 9: 784-8
|
|
|
|
|